SELLAS Life Sciences announced on November 17, 2026, that its Phase 3 REGAL trial met its primary endpoint of overall survival. The study tested galinpepimut-S (GPS), an investigational cancer vaccine, in people with acute myeloid leukemia (AML).
SELLAS reported median overall survival of 24.0 months for patients receiving GPS versus 14.7 months with investigator-selected best available treatment. The reported hazard ratio was 0.59 (a 41% lower risk of death), with a two-sided p-value of 0.035.
The trial enrolled 126 patients with AML who had reached a second or later remission and were not candidates for stem-cell transplant. GPS was studied as maintenance treatment.
The company said GPS was generally well tolerated, with treatment-related side effects mostly mild to moderate and often involving injection-site reactions.
SELLAS plans to discuss the findings and a possible accelerated filing strategy with the FDA, and has said it is preparing for a potential application in the first half of 2027. The vaccine remains investigational and is not approved.
Sources:
sec-gov-archives-edgar-data-1390478-000110465926128825-tm2629947d1-ex99-1-htm
sec-gov-archives-edgar-data-1390478-000110465926128825-tm2629947d1-8k-htm
Investigational Peptide Vaccine Demonstrates Survival Benefit ...
SELLAS Reports Positive Phase 3 Cancer Vaccine Trial Results
Sellas Life Sciences Says Cancer Vaccine Meets Primary Endpoint in Phase 3 Trial
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL
SELLAS REGAL Phase 3 trial cuts AML death risk 41% | SLS Stock News
Sellas' cancer vaccine slashes death risk by 41% in late-stage AML study
SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial
Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027
Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in ...
SELLAS Reports Positive Phase 3 Results for AML Vaccine, Plans FDA ...
SELLAS reports Phase 3 REGAL win as GPS extends median overall...